Q3 Revenue Jumps 24% to $102.9M, Full-Year Guidance Raised to $385-395M
CSTL sits 93% above its 52-week low of $17.722 on elevated volume (1.9× avg).
Summary
Castle delivered Q3 2026 revenue of $102.9 million, up 24% from $83.0 million a year ago, and raised full-year 2026 guidance to $385-395 million from $365-375 million. TissueCypher drove the beat with 15,574 test reports, up 47% year over year, while DecisionDx-Melanoma slipped to 10,177 reports from 10,459. Adjusted EBITDA rose to $12.7 million from $9.2 million, though GAAP net loss widened to $4.1 million ($0.13 per share) from $0.5 million, partly on a $3.4 million mark-to-market loss on equity securities. The company reaffirmed expectations for positive Adjusted EBITDA in Q4 2026, full-year 2026 and full-year 2027, backed by $277.7 million in cash and marketable securities. The guidance raise is the headline item for traders; the melanoma volume decline is the one soft spot to weigh against the TissueCypher ramp.
At the time of this announcement, CSTL was trading at $34.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $17.72 to $44.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.